Author:
Kim Jinkyoung,Lee Jiyun,Kim Chungyeul,Choi Jinhyuk,Kim Aeree
Funder
Korea Health Industry Development Institute (KHIDI) of Ministry of Health & Welfare (MOHW), Republic of Korea
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Group EBCTC. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.
2. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.
3. Osborne CK, Elledge RM, Fuqua SA. Estrogen receptors in breast cancer therapy. Sci Med. 1996;3:32–41.
4. Horwitz K, Jackson T, Bain D, Richer J, Takimoto G, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996;10(10):1167–77.
5. Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang Y, et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer. 2014;14(1):172.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献